$NBIO - Nascent CEO, Sean Carrick, commented: "We are thrilled to unlock the full disruptive potential of pritumumab against cancer by collaborating with Manhattan Bio's world-leading scientists."
https://finance.yahoo.com/news/nascent-biotec...00090.html